The StemSpine procedure using AlloStem cell therapy is intended for the treatment of chronic lower back pain. Credit: Africa Studio/Shutterstock.com.

Creative Medical Technology has received clearance from the Institutional Review Board (IRB) to initiate a Phase I/II clinical trial of the StemSpine procedure using AlloStem (CELZ-201-DDT) cell therapy to treat chronic lower back pain.

The FDA-approved, placebo-controlled, double-blind, randomised study is designed to assess the tolerability, efficacy and safety of CELZ-201-DDT.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

It intends to enrol 30 patients aged 18 to 80 with chronic lower back pain caused by degenerative disc disease.

Each cohort will include ten subjects who will receive six paraspinal intramuscular injections of low, medium, or high doses of CELZ-201-DDT or a placebo into the lumbar musculature under direct ultrasound guidance.

Evaluating the safety of CELZ-201-DDT in subjects experiencing chronic lower back pain at low, medium, or high doses for six months is the primary outcome measure of the study.

See Also:

Creative Medical Technology CEO Timothy Warbington said: “Studies show that 8% of all adults in the US, approximately 16 million people, experience chronic lower back pain.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“In addition to limiting their daily activities and negatively impacting their quality of life, many of those suffering rely on opioids as the standard of care, which carry their own side effects, not the least of which is addiction.

“We are hopeful that the outcome of this clinical trial will validate the efficacy, safety, and endurance of CELZ-201-DDT as a non-surgical treatment option for chronic lower back pain.”

AlloStem repairs and improves the blood supply around the disc and lower back area without exposing the patient to radiation, as compared to other cell-based procedures.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.